HC Wainwright & Co. Reiterates Buy on Palvella Therapeutics, Maintains $246 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Buy and maintains $246 price target.